Molecular Therapy

ASGCT Announces Joseph C. Glorioso, PhD, as Incoming Editor-in-Chief of Molecular Therapy

ASGCT & Molecular Therapy | May 09, 2024

Glorioso, a trailblazing gene therapy researcher and founding member of ASGCT, will assume the role on January 1, 2025.

Molecular Therapy
Read Full Story

Prenatal Delivery of a Therapeutic Antisense Oligonucleotide Achieves Broad Biodistribution in the Brain and Ameliorates Angelman Syndrome Phenotype in Mice

Wan Du, MD, PhD | April 11, 2024

Read our monthly summary of a Molecular Therapy article from the April issue of The Vector.

Molecular Therapy
Read Full Story

Hear Dr. Maxim Berezovski on the Molecular Therapy Podcast

Listen now! | February 13, 2024

Dr. Maxim Berezovski discusses a recent article published in Molecular Therapy Nucleic Acids.

Molecular Therapy  |  Podcasts
Read Full Story

Hear Dr. Richard Vile on the Molecular Therapy Podcast

Listen now! | January 09, 2024

Dr. Vile speaks with Dr. Timothy Cripe about his recent article, "Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses."

Molecular Therapy  |  Podcasts
Read Full Story

Mohamed Abou-el-Enein Appointed Editor of Molecular Therapy Methods and Clinical Development

Dr. Abou-el-Enein began five-year term Jan. 1. | January 04, 2024

The former associate editor-in-chief of MTMCD began his five-year term on Jan. 1.

ASGCT News  |  Molecular Therapy
Read Full Story

First Episode of Molecular Therapy Podcast Features Dr. Norbert Pardi

Listen now! | December 12, 2023

Listen to Dr. Pardi discuss his recent Molecular Therapy article, "Development of an mRNA-lipid Nanoparticle Vaccine Against Lyme Disease."

 

Molecular Therapy  |  Podcasts
Read Full Story

Apply to Become Molecular Therapy's Next Editor-in-Chief

Send your CV + cover letter by Jan. 31, 2024. | October 17, 2023

Submit your CV and a cover letter by Jan. 31, 2024.

Molecular Therapy
Read Full Story

Apply to Be the Next EIC of Molecular Therapy Methods & Clinical Development

Term Begins Jan. 2024 | June 30, 2023

The next editorial leader of MTMCD will assume the role on Jan. 1, 2024.

Molecular Therapy
Read Full Story

The Promise of Durable Remission in B-cell Malignancies With CAR-T Persistence

Courtney Bricker-Anthony, PhD | April 24, 2023

New research published in Molecular Therapy – Oncolytics shows a relationship between durable remission and the persistence of CAR-T cells in patients with B-cell malignancies.

Molecular Therapy
Read Full Story

Improving the efficiency of homology directed repair in gene editing

Courtney Bricker-Anthony, PhD | March 24, 2023

CRISPR/Cas9 has revolutionized the field of gene editing, but its efficiency in editing non-dividing, therapeutically relevant cells is limited by the induction of the error-prone non-homologous end joining repair pathway. Bak & colleagues developed an enrichment approach that promoted the efficiency of a more precise endogenous repair mechanism, homology directed repair (HDR), which led to greater numbers of successfully edited cells.

Molecular Therapy
Read Full Story

Transcribing a New Approach to Angelman Syndrome

Courtney Bricker-Anthony, PhD | February 01, 2023

Angelman syndrome is a severe neurogenetic disorder caused by the loss of UBE3A gene expression in the brain. In a recent Molecular Therapy paper, researchers showed how artificial transcription factors (ATFs) could be a promising approach to treating AS. Treated mice showed improvement in motor function, more activity in the open field test, and higher stride frequency than their untreated counterparts.

Molecular Therapy
Read Full Story

Meet New Editor-in-Chief of Molecular Therapy–Oncolytics: Dr. Tim Cripe

Devin Rose | January 19, 2023

Dr. Cripe assumed his role with Molecular Therapy Oncolytics on Jan. 1, replacing Yuman Fong, MD.

Molecular Therapy
Read Full Story

Engineering Improved Neuroprotection in Glaucoma

Courtney Bricker-Anthony, PhD | January 18, 2023

Researchers used AAV-mediated gene therapy in the eyes to enhance neuroprotection in mouse models of glaucoma—the leading cause of irreversible blindness. Intraocular injections resulted in partial recovery of visual behavior.

Molecular Therapy
Read Full Story

Doubling Down on Mitochondrial dsRNAs in Sjӧgren’s Syndrome

Courtney Bricker-Anthony, PhD | January 06, 2023

From the Molecular Therapy family: Read a summary on mitochondrial double-stranded RNAs and watch our first-ever video abstract.

Molecular Therapy
Read Full Story

In Molecular Therapy: EBAG9 silencing exerts immune checkpoint function without adverse effects

Jessica Schneller, PhD | November 22, 2022

Wirges et al demonstrate that EBAG9 downregulation in murine T cells and human CAR T cells augmented the cytolytic activity of these cells against hematopoietic tumors in vitro and in vivo.

Read Dr. Schneller's debut summary for The Vector!

Molecular Therapy
Read Full Story

Molecular Therapy Family's Impact Factor Increased 44 Percent in 2020

ASGCT Staff | July 01, 2021

Molecular Therapy-Oncolytics' 75% increase, to 7.200, was the highest impact factor jump across more than 50 Cell Press journals.

Molecular Therapy
Read Full Story
2024

Register for the 27th Annual Meeting

May 7-11, 2024 | Baltimore, MD

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.